Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
Journal Title: Annals of Hepatology - Year 2017, Vol 16, Issue 5
Abstract
Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-line drug. Evidence is building up in favor of fibrates, which are available for off-label use.
Authors and Affiliations
Cynthia Levy
Keywords
Related Articles
- EP ID EP208866
- DOI 10.5604/01.3001.0010.2709
- Views 114
- Downloads 0
Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery
Background: Obesity is the most frequent risk factor associated with NAFLD, and bariatric surgery (BAS) is traditionally indicated for the treatment of severely obese individuals. Here, we discuss the behavior and progno...
The burden of cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study
Background and rationale. Cirrhosis is responsible for significant health-care costs and morbidity. This study aims to evaluate the burden of illness associated with cirrhosis, its impact on the universal coverage public...
Bile acids and the Risk for Hepatocellular Carcinoma in Primary Biliary Cholangitis
This article does not has abstract.
Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection
Background and aim. Resistance-associated variants (RAVs) on the NS3 region of the hepatitis C virus (HCV) may be relevant for antiviral therapy, but data in human immunodeficiency virus (HIV) coinfected patients are sc...
Nonalcoholic steatohepatitis in morbid obese patients: coffee consumption vs. disease severity
Introduction. Obesity correlates with nonalcoholic fatty liver disease (NAFLD) and occurs in 90 to 100% of severely obese individuals (body mass index [BMI] > 35 kg/m2). Coffee consumption (CC) has been assoc...